<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454558</url>
  </required_header>
  <id_info>
    <org_study_id>12166</org_study_id>
    <secondary_id>2006-003520-10</secondary_id>
    <nct_id>NCT00454558</nct_id>
  </id_info>
  <brief_title>An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension</brief_title>
  <official_title>A Multicenter, Non-randomized, Non-blinded, Noncontrolled Study to Investigate the Impact of Multiple Doses of BAY 63-2521 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Pulmonary Hypertension in a 12-week 3 Times a Day Individual Dose Titration Scheme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to demonstrate the feasibility of an individual dose titration scheme based
      on the systolic blood pressure with a dose range from 1.0 mg TID to 2.5 mg TID. Patients
      suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial
      hypertension (PAH) will be included. After diagnosis by an expert center, patients receive
      medication three times a day starting with 1.0 mg TID. The first tablets are given in the
      hospital, then the patients are allowed to go home and take the medication at home. After 2
      weeks, patients return to the hospital for an ambulatory visit and the dose may be increased
      based on the actual condition of the patient (blood pressure and adverse events). Several
      measurements will be performed to test the efficacy of the drug and whether there are any
      unwanted reactions to the drug (blood tests, ECG, 6 minute walk test, imaging by Echo,
      quality of life scores). The dose of the drug will then be increased further until unwanted
      effects may occur or the blood pressure drops to low. The highest dose tested will be 2.5 mg
      TID. After 12 weeks the patient is going to stay in the hospital again and a right heart
      catheter is performed to examine the changes in hemodynamics after 12 weeks of treatment with
      the drug. If the patients give their consent they can enter a long-term extension trial
      continuing on BAY63-2521 with the dose reached after 12 weeks. Every 3 months an ambulatory
      visit at the specialist center will be performed including measurements of safety (blood
      tests, ECG, clinical assessment) and efficacy (6 minute walk test, Borg dyspnea scale, NT-pro
      BNP). Blood tests and ECG have been removed begin of 2013 as safety parameter by amendment 7;
      furthermore Borg dyspnea score and NT-proBNP have been removed as efficacy parameter.

      Initially the inclusion of ten patients suffering from chronic thromboembolic pulmonary
      hypertension (CTEPH) or pulmonary arterial hypertension (PAH) was planned. Later on the
      patient number was amended and 75 patients entered the trial.

      Furthermore the trial duration was extended and a long term treatment with BAY63-2521 was
      offered to the patients. Finally 68 patients moved over to the long term extension period of
      the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specification of primary outcome measures for long-term safety and tolerability: Adverse
      events, blood pressure and heart rate, 12 lead ECG, clinical chemistry and hematology,
      Troponin I
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety, tolerability and feasibility of individual titration of BAY63-2521 according to peripheral systolic blood pressure</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the long term safety and tolerability of BAY63-2521</measure>
    <time_frame>max. 84 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6MWT</measure>
    <time_frame>max. 84 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right heart catheter invasive hemodynamics</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO functional class assessment</measure>
    <time_frame>max. 84 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-pro BNP</measure>
    <time_frame>75 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging by echo</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <description>Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CTEPH or PAH in NYHA class II or III

        Exclusion Criteria:

          -  Patients with PDE 5 inhibitor or prostacycline pretreatment, relevant pulmonary
             diseases, relevant cardiac diseases, severe coagulation disorders, moderate to severe
             hepatic or renal insufficiency, pregnancy, hypotension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Löwenstein</city>
        <state>Baden-Württemberg</state>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results provided by Bayer.</description>
  </link>
  <results_reference>
    <citation>Belik J. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Curr Opin Investig Drugs. 2009 Sep;10(9):971-9. Review.</citation>
    <PMID>19705340</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, Grimminger F. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J. 2010 Oct;36(4):792-9. doi: 10.1183/09031936.00182909. Epub 2010 Jun 7.</citation>
    <PMID>20530034</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension (PAH)</keyword>
  <keyword>Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

